|
|
|
|
||
Re: FDA says off-label communications that are “consistent” with the approved label are acceptableI think Acadia may see accelerated increase earnings since a prescriber has the opportunity to use off label for psychosis. So whether psychosis from Parkinson's / lewy body disease. Or another entity. I've seen the antipsychotics use in palliative medicine in off label use. It's only a matter of time we will see cross utilization of nuplazid |
return to message board, top of board |